Tesamorelin calculators

A 5 mg tesamorelin vial mixed with 2 mL of bacteriostatic water gives 2.5 mg/mL. A 1 mg dose pulls 0.4 mL or 40 units — readable, repeatable. With daily injection, the vial covers 5 doses, so weekly refill cadence is the planning rhythm.

One Tesamorelin-specific failure mode worth knowing before you use the reconstitution math: Neglecting to systematically document and rotate injection sites, which can lead to localized lipohypertrophy that interrupts a planned daily schedule. Why was Tesamorelin studied with morning, rather than evening, administration? The morning administration schedule seen in most clinical literature is tied to Tesamorelin's extended half-life. Because it resists rapid breakdown and provides a prolonged GHRH signal for many hours, it does not need to be timed to coincide with the body's primary nocturnal growth hormone pulse. A morning dose provides a sustained level of GHRH receptor stimulation throughout the day, a profile that was extensively studied and established for its approved indication.

Vial size, diluent volume, and dose are the three inputs that genuinely change the answer. Doses-per-vial is a derived output — it's the vial mg divided by the dose mg, rounded down. The most common edge case is a tiny dose: at very high concentration, a 0.1 mL draw is only a few units on the syringe, which is hard to read accurately. If your unit count drops below five, consider reconstituting the next vial with more BAC water so each dose covers a larger volume.

The calculation to determine the correct syringe volume for a dose begins with the vial's total peptide content and the chosen volume of diluent. To illustrate with a common scenario, if a 5 mg vial of Tesamorelin is reconstituted using 2 mL of bacteriostatic water, the final concentration of the solution becomes 2.5 mg per mL. To draw a target dose of 1 mg, one would need to calculate the corresponding volume (1 mg divided by 2.5 mg/mL equals 0.40 mL), which converts precisely to 40 units on a U-100 insulin syringe.

Given the larger per-dose magnitude of Tesamorelin, the choice of diluent volume is a more significant planning variable than it is for microgram-dosed peptides. Using a smaller volume of bacteriostatic water (e.g., 1 mL in a 5 mg vial) will yield a highly concentrated solution, reducing the physical volume of the injection but potentially making very small dose adjustments difficult to measure. Conversely, using a larger diluent volume like 2 mL creates a less concentrated solution and a larger injection volume (e.g., 40 units for a 1 mg dose), which may improve measurement precision at the expense of requiring more careful injection site management.

When documenting the reconstitution process for tesamorelin, it is important to note the distinction between research-grade preparations and the pharmaceutical version, Egrifta. The latter is supplied in a kit with a specific volume of sterile water for injection, establishing a standardized final concentration. For individuals documenting personal research with a lyophilized powder vial, it is crucial to log the exact type and volume of the diluent used, such as bacteriostatic water. Recording this information ensures that all subsequent dose calculations logged in the platform are accurate and that the concentration can be audited against the planned protocol.